Biognosys

As researchers continue to explore uses for DDA and DIA workflows, mass spec advances are enabling both methods to generate larger and more complete data sets.

The company has licensed the Limited Proteolysis technology developed by ETH Zurich Professor Paola Picotti, which can assess proteome-wide structural changes.

Called CanPathPro, the research consortium aims to combine omics data and systems biology tools into a single commercial platform for testing cancer hypotheses.

The firm, which will open a Boston office at the end of Q1, did not disclose the amount raised but said it was in the "mid-single-digit millions" of dollars.

The effort will use Biognosys' HRM method to complement its MALDI-TOF approach to biomarker work, a company official said.

With sales growing at a double-digit clip, the Swiss proteomics firm is carving out a market for its mass spec-based protein quantitation services.